Next-Generation Imaging

Latest News

3d rendered medically accurate illustration of prostate cancer | Image Credit: @ SciePro - @ SciePro - stock.adobe.com
PSMA-PET leads imaging breakthroughs in prostate cancer paradigm

February 23rd 2024

Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging.

Study launches of BNT316/ONC-392 plus radioligand therapy in mCRPC
Study launches of BNT316/ONC-392 plus radioligand therapy in mCRPC

February 22nd 2024

Initial results published for 177Lu-rhPSMA-10.1 in mCRPC
Initial results published for 177Lu-rhPSMA-10.1 in mCRPC

February 20th 2024

64Cu-SAR-bisPSMA shows safety, efficacy in biochemically recurrent prostate cancer
64Cu-SAR-bisPSMA shows safety, efficacy in biochemically recurrent prostate cancer

February 15th 2024

18F-flotufolastat PET alters treatment approach for nearly 90% of patients with recurrent prostate cancer
18F-flotufolastat PET alters treatment approach for nearly 90% of patients with recurrent prostate cancer

February 12th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.